R&D channel feed – Endpoints News

R&D channel feed

Arvinas touts healthy volunteer data for Parkinson's disease PROTAC

Last month

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Last month

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data

Last month

Another TIGIT trial fails as BeiGene scraps Phase 3 drug

Last month

Novartis’ Chinook-originated kidney disease drug gets accelerated approval

Last month

Sarepta, Roche pause Elevidys trials in Europe following patient death

Last month

Edgewise's heart drug shows promise in Phase 2 trial

Last month

Axsome reports Phase 3 depression fail for Sunosi

Last month

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed

Last month

Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial

Last month

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Last month

RNA editing startup raises $155M to bring liver and lung disease therapy into clinic

Last month

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Last month

Tenaya to lay off about one-third of staff, reveals heart gene therapy data

Last month

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

Last month

Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer

Last month

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Last month

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

Last month

Marks’ exit at FDA rattles an already teetering biotech industry

Last month

Lilly's heart disease drug could be dosed as little as once a year, study shows

Last month

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Last month

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Last month

Vertex’s second-generation diabetes cell therapy fails early-stage study

Last month

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Last month

First page Previous page 1 2 345 6 7 Next page Last page